Showing results (11-20 of 37) with videos related to

Sort By:
Pageof 4
Journal of Gastroenterology|June 27, 2006
Visceral fat accumulation and insulin resistance are important factors in nonalcoholic fatty liver diseaseYuichiro Eguchi, Takahisa Eguchi, Toshihiko Mizuta, et al.
Medical Science Monitor : International Medical Journal of Experimental and Clinical Research|August 21, 2017
Seropositivity and Titers of Anti-Smooth Muscle Actin Antibody Are Associated with Relapse of Type 1 Autoimmune HepatitisTaro Shibuki, Taiga Otsuka, Hiroshi Isoda, et al.
Journal of Gastroenterology and Hepatology|April 1, 2008
Waist circumference correlates with hepatic fat accumulation in male Japanese patients with non-alcoholic fatty liver disease, but not in femalesEriko Ishibashi, Yuichiro Eguchi, Takahisa Eguchi, et al.
Hepatology Research : the Official Journal of the Japan Society of Hepatology|May 7, 2014
Pilot study of liraglutide effects in non-alcoholic steatohepatitis and non-alcoholic fatty liver disease with glucose intolerance in Japanese patients (LEAN-J)Yuichiro Eguchi, Yoichiro Kitajima, Hideyuki Hyogo, et al.
BMC Cancer|January 4, 2022
Prognostic nomogram for patients with unresectable pancreatic cancer treated with gemcitabine plus nab-paclitaxel or FOLFIRINOX: A post-hoc analysis of a multicenter retrospective study in Japan (NAPOLEON study)Taro Shibuki, Toshihiko Mizuta, Mototsugu Shimokawa, et al.
International Journal of Clinical Oncology|May 20, 2023
Scoring model with serum albumin and CA19-9 for metastatic pancreatic cancer in second-line treatment: results from the NAPOLEON studyAzusa Komori, Satoshi Otsu, Mototsugu Shimokawa, et al.
Anticancer Research|March 28, 2023
Conversion Surgery for Unresectable Pancreatic Cancer Treated With FOLFIRINOX or Gemcitabine Plus Nab-paclitaxelYasushi Ide, Taiga Otsuka, Mototsugu Shimokawa, et al.
International Journal of Clinical Oncology|January 23, 2021
A multicenter propensity score analysis of FOLFIRINOX vs gemcitabine plus nab-paclitaxel administered to patients with metastatic pancreatic cancer: results from the NAPOLEON studyTaiga Otsuka, Tsuyoshi Shirakawa, Mototsugu Shimokawa, et al.
Pancreas|August 4, 2021
Gemcitabine Plus Nab-Paclitaxel Versus FOLFIRINOX in Locally Advanced, Unresectable Pancreatic Cancer: A Multicenter Observational Study (NAPOLEON Study)Shiho Arima, Machiko Kawahira, Mototsugu Shimokawa, et al.
Anticancer Research|July 7, 2021
Gemcitabine Plus Nanoparticle Albumin-bound Paclitaxel Versus FOLFIRINOX for Recurrent Pancreatic Cancer After ResectionHiroki Taguchi, Taiga Otsuka, Mototsugu Shimokawa, et al.
Pageof 4